Outlook Therapeutics reports executive or director departure via 8-K filing

Outlook Therapeutics filed an 8-K disclosing a change in corporate governance or executive leadership under Item 5.02. The filing confirms a departure or appointment, though specific names and implications for company strategy remain to be detailed in the full exhibit.